Replies to post #32248 on Ocata Therapeutics Inc fka OCAT

[mvecho]

Thanks Rocky and Rumit for your help! Everything makes sense now. I only get a few posts a month because i have not upgraded so i'd like to say that i read everyones post Monday thru Friday and i really enjoy what everyone has to say. Cheers!

[north40000]

Am I mistaken? This sounds like a delay:

That change would allow ACT's five single-blastomere lines currently under review at the NIH to receive federal funding for research, if approved by the agency. ACT currently has an investigational new drug application (IND) under review at the FDA for a Phase I/II trial using its MA09 single-blastomere line to treat Stargardt disease, a genetic condition and the leading cause of juvenile blindness in the U.S., Lanza told BioWorld Today.

The IND currently is on hold while ACT addresses some of the FDA's questions, but Lanza said the company is hoping to initiate the study by the end of the third quarter.